CureVac files patent infringement lawsuit against BioNTech over mRNA technology
According to CureVac, its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which were used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine.